HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116
HZNP-HZN-1116-201
Phase 2 small_molecule active
Quick answer
HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116 for Sjögren’s Syndrome is a Phase 2 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Elan Pharma International
- Indication
- Sjögren’s Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active